Resources for Payers

  

Links

Referenced-EEG® (rEEG®) is a biomarker-based test that guides doctors to medications that work, individualized to the patient. It is used in an area where psychotropic drugs have typically performed poorly, usually health plan members with treatment-resistant mental disorders and who drive a significant share of health care costs. The results are astonishing: 70-85% improvement in patients where 16% improvement is typical.

Principal impacts of deploying rEEG® within a health plan include:

  • Improved health outcomes (including reduced inpatient utilization) for treatment-resistant patients
  • Improved economic outcomes (including prescription costs) for high cost cases
  • Administrative efficiency
  • Criteria-based method for handling reimbursement requests for VNS, rTMS, DBS, and even ECT
  • Improved patient work and home functioning leading to a reduction in indirect costs

In recent years, over 5,000 treatment-resistant patients have participated in Referenced-EEG® programs, with an average 75% improvement in outcomes1. CNS Response now provides a turnkey service for selected payers interested in evaluating reimbursement and national deployment of rEEG® for psychiatric medication management. Operating much like a reference lab, rEEG® services are recommended as a complement to traditional Disease Management and Managed Behavioral Health programs for the highest cost, treatment resistant patients where traditional medicine has failed.

A growing body of evidence supports use of physiological biomarkers and imaging technologies such as EEG, SPECT and fMRI to guide effective, patient-centered treatment. Referenced-EEG® has been particularly effective in the treatment of high cost treatment-refractory patients with a range of diagnoses including major depressive, bipolar, attention deficit, anxiety, addictive, and eating disorders. In fact, a recent study released by the Center for Health Economics, Epidemiology, and Science Policy said this:

In conclusion, the evidence supporting the use of rEEG® is at least comparable to evidence supporting other modes of treatment for TRD and, on some occasions, superior. 2

To learn how rEEG can have a positive impact on payer organizations select the above page links to read additional information on rEEG's efficacy, economics and evidence.

 

 

1 Defined as an improvement of 2 or more gradations on the Clinical Global Improvement (CGI) scale.

2 Comparing Levels of Evidence for Treatment of Treatment-Resistant Depression with Referenced-EEG to Current Practice, UBC, July 2008

 

 

  

> Better Efficacy

> Better Economics

> Better Evidence
 
Copyright 2010 CNS Response